ATR-FTIR Sensor for Label-Free Drug Preselection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for monitoring the efficacy of potential drugs on secondary structure distribution of target biomolecules, particularly in neurodegenerative diseases like Alzheimer's, are limited by lack of spectral and structural resolution, requiring label-based assays, and are not suitable for early-stage diagnosis or mass screening.
Innovation Solution
A label-free, real-time method using an ATR-FTIR sensor with a chemically modified germanium surface and antibodies to detect secondary structural changes in biomarkers like Tau and Aβ 1-42, allowing direct analysis of drug interactions in complex body fluids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If surface plasmon resonance (SPR) or quartz crystal microbalance (QCM) techniques are used to analyze protein-drug interactions, then kinetic information can be obtained, but spectral and structural resolution is lost making it impossible to monitor secondary structure distributions
Solution Approach 1:
The patent combines the kinetic analysis capability of SPR/QCM with the spectral resolution of FTIR spectroscopy by integrating an FTIR sensor into the protein-drug interaction analysis system, enabling simultaneous monitoring of both kinetic parameters and secondary structure changes
Solution Approach 2:
The patent employs a universal FTIR-based platform that can simultaneously provide kinetic information, spectral resolution, and secondary structure analysis, making a single technique capable of performing multiple functions that previously required separate methods
2Productivity
If high-throughput chemical microarray surface plasmon resonance (HT-CM-SPR) is used to identify small molecules binding to target proteins, then binding can be detected, but effect on secondary structure cannot be detected due to lack of spectral resolution
Solution Approach 1:
The patent merges the high-throughput screening capability of HT-CM-SPR with the secondary structure detection capability of FTIR spectroscopy, creating a platform that maintains productivity while adding spectral resolution for structural analysis
3Measurement precision
If surface enhanced Infrared absorption (SEIRA) spectroscopy is used to provide spectral resolution, then secondary structure can be analyzed, but reproducibility is very challenging due to preparation of rough gold surfaces
Solution Approach 1:
The patent uses disposable, pre-prepared sensor surfaces that eliminate the need for complex and variable rough surface preparation, ensuring consistent and reproducible results while maintaining the spectral resolution benefits of enhanced infrared absorption
Solution Approach 2:
The patent changes the physical state and preparation method of the sensor surface from rough metal surfaces requiring complex preparation to smoothly coated surfaces with standardized procedures, improving reproducibility while maintaining analytical capability
4Measurement precision
If PET or MRT techniques are used to detect aggregates in the human brain, then drug effect in vivo can be analyzed at later stages, but the techniques are very expensive and time-consuming making them unsuitable for mass screening
Solution Approach 1:
The patent creates an in vitro copy of the in vivo system using body fluids (CSF, plasma, serum) that contain the actual patient-specific misfolded proteins, allowing screening and analysis at lower cost and time investment while maintaining biological relevance
Solution Approach 2:
The patent performs preliminary analysis of drug effects on misfolded proteins using in vitro FTIR spectroscopy on body fluid samples before proceeding to expensive in vivo imaging, enabling preselection of promising candidates and reducing overall research cost and time
5Measurement precision
If PET techniques are used for in vivo analysis, then contrast agents are required which stress the patients, but label-free analysis is not available
Solution Approach 1:
The patent utilizes the inherent infrared absorption properties of the misfolded proteins themselves in body fluid samples, requiring no external labels, tags, or contrast agents, thereby eliminating patient stress while maintaining analytical capability
Solution Approach 2:
The patent creates an in vitro model using patient body fluids that preserves the native state of misfolded proteins without requiring contrast agents, allowing label-free analysis that avoids patient stress while maintaining biological accuracy
6Measurement precision
If fluorescence based immuno assays like ELISA or sFIDA are used, then sensitivity can be improved, but the need of fluorescent labelled antibodies influences the secondary structure distribution of the target protein
Solution Approach 1:
The patent employs the intrinsic infrared absorption properties of the target proteins for detection, eliminating the need for fluorescent labels or other tags that could interfere with protein structure, thereby maintaining both sensitivity and structural integrity
Solution Approach 2:
The patent replaces the fluorescence-based detection mechanism with infrared absorption spectroscopy, substituting a label-dependent optical method with a label-independent vibrational spectroscopy method that directly probes protein secondary structure
7Quantity of substance
If Western blots are used to analyze aggregation state, then molecular weight information can be obtained, but the native secondary structure of the protein is lost due to preparation process
Solution Approach 1:
The patent replaces the Western blot mechanical preparation process with direct infrared spectroscopic analysis of body fluid samples, substituting a method that requires protein extraction and electrophoresis with a technique that analyzes proteins in their native state in solution
Solution Approach 2:
The patent uses the native proteins directly from body fluids as the analytical sample, creating a true copy of the in vivo state without requiring extraction, separation, or structural disruption procedures
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables precise monitoring of drug-induced secondary structural changes, providing direct evidence of drug efficacy in vitro and preselecting potential candidates for neurodegenerative diseases, overcoming limitations of existing techniques.
Implementation Method 1
monitoring a secondary structural change by vibrational spectroscopy
Implementation Method 2
Fourier-transform infrared (FTIR-) spectroscopy has been described for the analysis of recombinant and purified proteins
Implementation Method 3
an infrared sensor element having an internal reflection element with a core of an infrared transparent material
Data Source
Figure 1
Figure 2A~3
Figure 4~6
AI summary
The invention provides a method that gives direct information about the intervention of a potential drug on the secondary structure distribution of a targetbiomolecule, i.e., for a disease with misfolded protein, such as neurodegenerative diseases in a complex body fluid. The secondary structural change is monitored by vibrational spectroscopy. The method can be applied for prescreening of drug candidates for targeting of specific biomolecules. The effect of the drug on the secondary structure distribution is monitored label-free in real time and provides thereby direct information about the efficacy of the potential drug.